ArticleACS nano2009
Functional delivery of siRNA in mice using dendriworms.
Article in ACS nano, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 5 citations in OpenAlex.
- The landscape of nanoparticle-based siRNA delivery and therapeutic development.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Review
- Cyclodextrin-Based Nanostructure Efficiently Delivers siRNA to Glioblastoma Cells Preferentially via Macropinocytosis.International journal of molecular sciences · 2020Article
- Metal Oxide Nanoparticles as Biomedical Materials.Biomimetics (Basel, Switzerland) · 2020Review
- Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery.Advanced materials (Deerfield Beach, Fla.) · 2019Review
- Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach.International journal of nanomedicine · 2019Review
- Dendrimer- and copolymer-based nanoparticles for magnetic resonance cancer theranostics.Theranostics · 2018Review
- Function Oriented Molecular Design: Dendrimers as Novel Antimicrobials.Molecules (Basel, Switzerland) · 2017Review
- Review
- Salicylic Acid Conjugated Dendrimers Are a Tunable, High Performance CEST MRI NanoPlatform.Nano letters · 2016Article
- Strategies to target drugs to gliomas and CNS metastases of solid tumors.Journal of neurology · 2016Review
- Second Generation Amphiphilic Poly-Lysine Dendrons Inhibit Glioblastoma Cell Proliferation without Toxicity for Neurons or Astrocytes.PloS one · 2016Article
- Progress and perspective of inorganic nanoparticle-based siRNA delivery systems.Expert opinion on drug delivery · 2016Review
- Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.Journal of neuro-oncology · 2015Review
- Bionanotechnology and the future of glioma.Surgical neurology international · 2015Article
- Nanocarrier-based therapies for CNS tumors.CNS oncology · 2014Review
- Dendrimer advances for the central nervous system delivery of therapeutics.ACS chemical neuroscience · 2014Review
- Functional nanostructures for effective delivery of small interfering RNA therapeutics.Theranostics · 2014Review
- Anti-epidermal growth factor receptor siRNA carried by chitosan-transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide.International journal of nanomedicine · 2014Article
- Diseases originate and terminate by genes: unraveling nonviral gene delivery.Drug delivery and translational research · 2013Article
- Self-assembled nanoparticles based on modified cationic dipeptides and DNA: novel systems for gene delivery.Journal of nanobiotechnology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
Small interfering RNAs (siRNAs) mediate cleavage of specific, complementary mRNA sequences and thus regulate gene expression. Not surprisingly, their use for treatment of diseases that are rooted in aberrant gene expression, such as cancer, has become a paradigm that has gained wide interest. Here, we report the development of dendrimer-conjugated magnetofluorescent nanoworms that we call "dendriworms" as a modular platform for siRNA delivery in vivo. This platform maximizes endosomal escape to robustly produce protein target knockdown in vivo, and is tolerated well in mouse brain. We demonstrate that siRNA-carrying dendriworms can be readily internalized by cells and enable endosomal escape across a wide range of loading doses, whereas dendrimers or nanoworms alone are inefficient. Further, we show that dendriworms carrying siRNA against the epidermal growth factor receptor (EGFR) reduce protein levels of EGFR in human glioblastoma cells by 70-80%, 2.5-fold more efficiently than commercial cationic lipids. Dendriworms were well-tolerated after 7-days of convection-enhanced delivery to the mouse brain and in an EGFR-driven transgenic model of glioblastoma, anti- EGFR dendriworms led to specific and significant suppression of EGFR expression. Collectively, these data establish dendriworms as a multimodal platform that enables fluorescent tracking of siRNA delivery in vivo, cellular entry, endosomal escape, and knockdown of target proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.